Stocks To Buy Today: ITC, Devyani International, Sun Pharma, Alkem Labs And More

Analysts have given recommendations for companies including ITC Ltd., Devyani International Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., and more.

As per the stock calls shared with NDTV Profit, these companies could see upside of as much as 14% from current levels. These stocks have already yielded as much as nearly 127% in the past 12 months.

Here are the top stocks to buy, as per Aamar Deo Singh, senior vice president, research at Angel One Ltd., Sudeep Shah, deputy vice president and head of tech & derivatives research at SBICAP Securities, Nilesh Jain, head, vice president, technical & derivatives research at Centrum Broking and Aditya Arora, founder and multi asset research analyst at Adlytick.in.

Star Cement stock can be bought in the range of Rs 230 to Rs 232 per share, with price target at Rs 269, according to Angel One's Singh. He recommends putting the stop loss for the stock at Rs 209.

The stock has risen 37.01% in the past 12 months and advanced 33.35% in the year-to-date period. Relative strength index for the counter stands at 65.60.

Of the 13 analysts tracking the stock, 10 recommend 'buy', one has a 'hold' call, while two recommend a 'sell'. The consensus 12-month price target for the share price is Rs 214.10 per share, implying a downside potential of 9.8%.

Shah of SBICAP Securities suggests buying Amber Enterprises at Rs 6,900 with a target of Rs 7,150, with a stop loss at Rs 6,760.

Amber Enterprises share price has risen 127.14% in the past 12 months, and 122.38% year-to-date. The RSI for the stock stands at 74.44.

Of the 27 analysts tracking the stock, 17 recommend 'buy', eight recommend 'hold', and two 'sell'. The consensus 12-month analysts' price target for the share price is Rs 6,710.73, implying a downside potential of 2.9%.

Shah also has a buy call on pharmaceutical company Jubilant Ingrevia at Rs 800, with a target price of Rs 845. Stop loss for the counter should be pegged at Rs 780, he suggests.

The stock has given 59.23% returns in the past 12 months, and 61.12% in the year-to-date period. The RSI for the stock is 54.55.

Of the five analysts tracking the stock, two recommend 'buy', two 'hold' and one has 'sell'. The consensus 12-month analysts' price target for the share is Rs 704.75, implying a downside of 12%.

Nilesh Jain recommends buying Devyani International stock with the target at Rs 184. He calls for keeping the stop loss at Rs 173.

The scrip has fallen 6.49% in the past 12 months, while the year-to-date returns fell 6.71%. The RSI for the counter is 6106.

Of the 25 analysts tracking the stock, 17 recommend 'buy', two 'hold' and six 'sell'. The consensus 12-month analysts' price target for the share is Rs 185.75, implying an upside potential of 4.8%.

Alkem Labs stock has received a 'buy' call from Singh. The market expert recommends buying the stock at a price of Rs 5,450, with the target at Rs 5,667 per share and stop loss at Rs 5,337.

Stock has risen 9.53% in the past 12 months and 5.02% in the year-to-date period. RSI of the stock is 43.61.

Of the 23 analysts tracking the stock, 10 recommend 'buy', eight 'hold' and five 'sell'. The consensus 12-month analysts' price target for the share is Rs 5,720.32 , implying an upside potential of 4.3%.

Aditya Arora from Adlytick has a buy call on ITC at Rs 474, with a target price of Rs 490. Stop loss for the counter should be pegged at Rs 558, he suggests.

The stock has given 4.04% returns in the past 12 months, and 0.97% in the year-to-date period. The RSI for the stock is 53.50.

Of the 38 analysts tracking the stock, 33 recommend 'buy', three 'hold' and two 'sell'. The consensus 12-month price target for the share is Rs 539.49, implying an upside potential of 13.8%

Arora also recommends buying Sun Pharma stock at Rs 1,815 with the target at Rs 1,865 and then Rs 1,875. He calls for keeping the stop loss at Rs 1,760.

The scrip has risen 45.48% in the past 12 months, while the year-to-date returns stand at 40.02%. The RSI for the counter is 52.39.

Of the 41 analysts tracking the stock, 30 recommend 'buy', seven 'hold' and four 'sell'. The consensus 12-month analysts' price target for the share is Rs 2,045.41, implying an upside potential of 12.7%.